Rare-disease specialist Catalyst Pharmaceuticals is set to be acquired by healthcare group Angelini Pharma in a $4.1 billion deal. Angelini will pay $31.50 for each of Nasdaq-listed Catalyst’s ...
With an eye on the lucrative U.S. market, Italy’s Angelini Pharma will acquire rare disease specialist Catalyst Pharmaceuticals and its potential blockbuster, Firdapse, for $4.1 billion. Rome-based ...
Angelini Pharma has agreed to acquire all outstanding shares of Catalyst Pharmaceuticals (CPRX) for $31.50 per share in cash, for a total equity value of approximately $4.1B. The deal has been ...
Scientists have engineered a highly selective catalyst that can convert methane, a major component of natural gas, into methanol, an easily transportable liquid fuel, in a single, one-step reaction.
Organocatalytic annulations represent a powerful strategy for the construction of cyclic frameworks using exclusively organic catalysts. By leveraging chiral amines, phosphines or cinchona alkaloid ...
State-backed CDP Equity to have a stake in combined entity Deal comes after Chiesi's $1.9 billion buyout of U.S. KalVista Angelini aims to create global player in rare disease drugs ROME/MILAN, May 7 ...
SANTA CRUZ — A small group of music fans and Santa Cruz City Council candidates have created a petition in hopes of saving the Catalyst Club in downtown Santa Cruz. The building at 1011 Pacific Ave.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results